Drugs.com Clinical Trial ResultsOriginal article
Modified HIV Drug Reverses Vision Loss and Paralysis in Multiple Sclerosis Model
Data Readoutpositivekamuvudine-9Positive
AI Analysis
Summary
NIH-funded research demonstrates that experimental drug kamuvudine-9, a modified HIV drug, reverses vision loss and paralysis in animal models of multiple sclerosis. This preclinical finding suggests potential therapeutic applications for MS-related neurological symptoms.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Experimental drug facilitates recovery from pre-existing vision loss and paralysis in animal models of multiple sclerosis
Importance:5/10
Sentiment:
0.70
multiple sclerosispreclinicalvision lossparalysisHIV drugNIH funded
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 23, 2026 1:09 AM